Author Topic: Tolebrutinib (Read 161 times)

agate · « **on:** August 22, 2021, 08:37:31 pm »

Trials of tolebrutinib will move to phase 3, apparently. The abstract indicates that some of this trial's participants were people with relapsing secondary progressive MS, and that the phase 3 trial would include relapsing and progressive forms of MS.

From PubMed (August 22, 2021)--"Safety and efficacy of tolebrutinib, an oral brain-penetrant PTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial":

https://pubmed.ncbi.nlm.nih.gov/34418400/

agate · « **Reply #1 on:** November 12, 2021, 09:16:09 pm »

This article is from Spherix Global Insights (November 4, 2021), a market intelligence firm. It is very badly written but it looks as if tolebrutinib may be the first ever MS drug that will be meant to treat all progressive forms of MS, including SPMS that isn't considered active. I do not know what PfMS means but am guessing that it stands for "progressive forms of MS."

https://bit.ly/3wOPH6X

agate · « **Reply #2 on:** November 13, 2021, 09:49:44 pm »

More on tolebrutinib in PharmaTime (October 13, 2021)--"Sanofi's BTK inhibitor tolebrutinib shows 'promising' long-term MS data":

https://www.pharmatimes.com/news/sanofis_btk_inhibitor_tolebrutinib_gains_promising_long-term_ms_data_1380733

MS Speaks

Author Topic: Tolebrutinib (Read 161 times)

agate

Tolebrutinib

agate

Tolebrutinib for all types of progressive MS

agate

Sanofi's BTK inhibitor tolebrutinib shows "promising" MS data